Quarterly Result29 May 2026, 09:38 pm
Bafna Pharma: FY26 Revenue ₹8,213.83 Lakhs
AI Summary
Bafna Pharmaceuticals Ltd announced its audited financial results for the quarter and year ended March 31, 2026. Key highlights include revenue from operations of ₹8,213.83 lakhs and the Board's approval of these results on May 29, 2026. The company is contesting GST demands and recovery of GST refunds, but anticipates no adverse financial outcome. The auditor's report has an unmodified opinion.
Key Highlights
- Bafna Pharma's Board approved audited financial results for FY26 on May 29, 2026.
- FY26 revenue from operations stood at ₹8,213.83 lakhs.
- The company is contesting GST demands of ₹235.47 Lakhs and GST refunds recovery of ₹331.09 Lakhs.
- Auditor's report for FY26 has an unmodified opinion.
- Board meeting commenced at 02.00 P.M and concluded at 04.00 P.M.
Price Impact
More from BAFNAPHARM